~~<i id='B702B57AEB'><strike id='B702B57AEB'><tt id='B702B57AEB'><pre id='B702B57AEB'></pre></tt></strike></i>~~

Home» leisure time» comprehensive

comprehensive

author：explore 2025-09-29 05:28:39 Page View：66412

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biotech incubator Curie.Bio graduates its first startup
Next article： How to save PrEP access — and even expand it

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

AdobeLife-sciencecompanieshavechangedtheworldwiththebreakthroughvaccinesandtherapeuticstheycreated—a

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

VictorSeguraIbarraandRitaSerda,Ph.D.,NCI,NIHTheFoodandDrugAdministrationonWednesdayapprovedafuturist

WSS

comprehensive

comprehensive

focus

Wikipedia

Pioneering cancer drug will cost $475,000. Analysts call it a bargain